Anti-myeloperoxidase (MPO) antibodies are primarily associated with ANCA-associated vasculitis, most commonly microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA).
Presence of antibodies aids diagnosis; in patients with known disease, measurement of antibody concentrations over time can be used as a prognostic indicator and may be useful in identification of disease flare and remission.
The clinical relevance of anti-MPO outside of vasculitis (e.g. inflammatory bowel disease) is uncertain.
Anti-PR3, with anti-MPO testing is automatically reflexed internally from indirect immunofluorescence ANCA testing.
For urgent/rapid testing (vasculitis screen MPO,PR3 and GBM) please telephone the Immunology laboratory.
Please note method change from 27/10/2023; different measurement units apply, quantitative results between methods are NOT comparable.
Ambient (8 - 24 degrees Celsius)
300uL serum (minimum) ,1 mL serum (preferred)
P-ANCA (of anti-MPO specificity) are found in up to 50 percent of patients with microscopic polyarteritis and pauci-immune glomerulonephritis, in addition to rheumatoid arthritis, SLE and ulcerative colitis.
Normal: <20 CU
Positive: >20 CU
$55.00 (Exclusive of GST)
Myeloperoxidase antibodies (MPO-ANCA) are tested on all positive ANCA samples.
"*" indicates required fields